Therapeutic Asset Ratings

3,272 results matching 1 filter

91,583 assets · 7,906 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
FAPI74 Cholangiocarcinoma	National Cancer Institute (NCI)	P2	CCC (54)
Floxuridine Cholangiocarcinoma	National Cancer Institute (NCI)	P2	CCC (54)
Herzuma Breast Cancer	National Cancer Institute (NCI)	P2	CCC (54)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER Urinary Bladder Carcinoma	National Cancer Institute (NCI)	P2	CCC (54)
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER Colorectal Cancer	National Cancer Institute (NCI)	P2	CCC (54)
IMMUNOTHERAPIC BIFUNCTIONAL FUSION PROTEIN COMPRISED OF A FULLY HUMAN IGG1 MONOCLONAL ANTIBODY (AVELUMAB) AGAINST HUMAN PROGRAMMED DEATH-LIGAND 1 (PD-L1) FUSED TO THE SOLUBLE EXTRACELLULAR DOMAIN OF TRANSFORMING GROWTH FACTOR-.BETA. (TGF-.BETA.) RECEPTOR II, WHICH ACTS AS A TGF-.BETA. TRAP Anal Carcinoma	National Cancer Institute (NCI)	P2	CCC (54)
IMMUNOTHERAPIC BIFUNCTIONAL FUSION PROTEIN COMPRISED OF A FULLY HUMAN IGG1 MONOCLONAL ANTIBODY (AVELUMAB) AGAINST HUMAN PROGRAMMED DEATH-LIGAND 1 (PD-L1) FUSED TO THE SOLUBLE EXTRACELLULAR DOMAIN OF TRANSFORMING GROWTH FACTOR-.BETA. (TGF-.BETA.) RECEPTOR II, WHICH ACTS AS A TGF-.BETA. TRAP Castration-Resistant Prostate Carcinoma	National Cancer Institute (NCI)	P2	CCC (54)
IMMUNOTHERAPIC BIFUNCTIONAL FUSION PROTEIN COMPRISED OF A FULLY HUMAN IGG1 MONOCLONAL ANTIBODY (AVELUMAB) AGAINST HUMAN PROGRAMMED DEATH-LIGAND 1 (PD-L1) FUSED TO THE SOLUBLE EXTRACELLULAR DOMAIN OF TRANSFORMING GROWTH FACTOR-.BETA. (TGF-.BETA.) RECEPTOR II, WHICH ACTS AS A TGF-.BETA. TRAP Human Papilloma Virus Infection	National Cancer Institute (NCI)	P2	CCC (54)
Ipilimumab Endometrial Carcinoma	National Cancer Institute (NCI)	P2	CCC (54)
Loperamide Endometrial Carcinoma	National Cancer Institute (NCI)	P2	CCC (54)
Nilotinib Cholangiocarcinoma	National Cancer Institute (NCI)	P2	CCC (54)
Nilotinib Colorectal Neoplasm	National Cancer Institute (NCI)	P2	CCC (54)
Nilotinib Ovarian Neoplasm	National Cancer Institute (NCI)	P2	CCC (54)
PANITUMUMAB Ovarian Carcinoma	National Cancer Institute (NCI)	P2	CCC (54)
Vismodegib Urinary Bladder Carcinoma	National Cancer Institute (NCI)	P2	CCC (54)
Abemaciclib Colorectal Carcinoma	National Cancer Institute (NCI)	P1/2	CCC (54)
Ipilimumab Cutaneous Neuroendocrine Carcinoma	National Cancer Institute (NCI)	P1/2	CCC (54)
Ipilimumab Skin Squamous Cell Carcinoma	National Cancer Institute (NCI)	P1/2	CCC (54)
Ipilimumab Classic Hodgkin Lymphoma	National Cancer Institute (NCI)	P1/2	CCC (54)
Irinotecan Digestive System Carcinoma	National Cancer Institute (NCI)	P1/2	CCC (54)
Nivolumab Central Nervous System Neoplasm	National Cancer Institute (NCI)	P1/2	CCC (54)
Oxodotreotide Neuroendocrine Carcinoma	National Cancer Institute (NCI)	P1/2	CCC (54)
Oxodotreotide Pheochromocytoma-Paraganglioma	National Cancer Institute (NCI)	P1/2	CCC (54)
PREDNISONE TABLETS Cutaneous Neuroendocrine Carcinoma	National Cancer Institute (NCI)	P1/2	CCC (54)
Trastuzumab Deruxtecan Gastric Cancer	National Cancer Institute (NCI)	P1/2	CCC (54)

Showing 976 to 1000 of 3,272 assets

PreviousPage 40 of 131Next